在非小细胞肺癌 (NSCLC) 治疗中,药理学驱动的依赖序列的协同效应:通过序列间隔优化协同效应
1Center of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing 211198, China.
Pharmaceutics
|August 28, 2025
概括
通过优化药物相互作用,连续佩米特雷克斯 (PEM) 和奥西米丁 (OSI) 化学疗法的48小时间隔最大限度地提高了EGFR突变非小细胞肺癌 (NSCLC) 的疗效.
科学领域:
- 癌症学
- 药理学
- 分子生物学
背景情况:
- 在表皮生长因子受体 (EGFR) 突变非小细胞肺癌 (NSCLC) 治疗中,Pemetrexed (PEM) 和Osimertinib (OSI) 联合治疗具有前景.
- 连续PEM→OSI治疗的最佳时间表尚未确定,并且剂量间隔对协同作用的影响尚未研究.
研究的目的:
- 研究PEM和OSI之间的药理学相互作用.
- 在EGFR突变NSCLC中确定顺序PEM→OSI给药的最佳剂量间隔.
主要方法:
- 将PEM药动力学划分为OSI对抗早期和OSI协同后期阶段.
- 在各种单一疗法和连续组合疗法下评估细胞周期,DNA损伤,细胞亡和EGFR信号通路.
- 评估了不同剂量间隔 (24小时与48小时) 对连续PEM → OSI治疗的影响.
主要成果:
- 通过特定的分子机制,OSI对抗PEM的早期阶段,但增强晚期细胞灭绝.
- 在PEM → OSI的48小时间隔中,药物暴露与协同药理动力学阶段保持一致,从而产生强大的协同作用.
- 24小时间隔显示出有限的协同作用,而并发或反转的序列产生了减弱的效果.
结论:
- 连续PEM→OSI的48小时间隔通过优化时间药物相互作用来最大限度地提高治疗效果.
- 这种药理学导向的疗法为EGFR突变NSCLC的临床应用提供了有前途的策略.
更多相关视频
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
12.3K
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
7.4K
相关概念视频
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Combined Effects of Drugs: Synergism
4.7K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
4.7K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Structure-Activity Relationships and Drug Design
1.0K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.0K
